GlassScriptPhysician profile
Yasir Al-Azzawi
NPI 1942597018
$7,381.63
in general payments reported to CMS, 2019-2025
32 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.00 · 2020: $91.49 · 2021: $382 · 2022: $525 · 2023: $1,509 · 2024: $2,057 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,170 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,170.32 |
| Education | $113.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,426.34 | 2019-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $1,324.03 | 2020-2025 | Rinvoq, Linzess, Viberzi |
| Pfizer INC. | $451.20 | 2024-2025 | |
| Celgene Corporation | $442.12 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $435.28 | 2024-2025 | Wegovy |
| Lilly USA, LLC | $430.62 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $388.32 | 2021-2025 | Entyvio, Eohilia |
| Medtronic, INC. | $368.71 | 2023 | Interstim |
| Genzyme Corporation | $287.11 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.77 | 2022-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $175.45 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $166.98 | 2023-2024 | Zymfentra, Vegzelma, Yuflyma |
| Boston Scientific Corporation | $165.78 | 2021-2025 | Watchman Flx |
| Janssen Scientific Affairs, LLC | $139.70 | 2020-2022 | |
| Madrigal Pharmaceuticals | $138.57 | 2025 | Rezdiffra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $107.91 | 2023-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $105.02 | 2022-2025 | Ocaliva |
| Ardelyx, INC. | $100.12 | 2024-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $92.91 | 2022-2024 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.82 | 2023 | Cyltezo |
| Organon LLC | $58.50 | 2023 | Hadlima, Renflexis |
| Gilead Sciences, INC. | $54.98 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $42.73 | 2023-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $38.43 | 2022-2024 | Rebyota |
| Vivus LLC | $31.94 | 2024-2025 | Pancreaze, Qsymia |
| Aimmune Therapeutics, INC. | $28.83 | 2025 | Vowst |
| Ipsen Biopharmaceuticals, INC | $28.12 | 2023 | Bylvay |
| Regeneron Healthcare Solutions, INC. | $22.71 | 2025 | Dupixent |
| Biocon Biologics INC | $22.52 | 2025 | Yesintek |
| Amgen INC. | $21.07 | 2023 | Amjevita |
| Lucid Diagnostics INC. | $18.34 | 2023 | |
| Axonics, INC. | $15.70 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasir Al-Azzawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.